Glycosmedia - an international diabetes news service from the UK
News
  Improving the delivery of adult diabetes care through integration
  Sharing experience and learning (Diabetes UK)
   
  Preventing type 2 diabetes: population and community-level interventions
  Evidence Update October 2014 (NICE)
   
  Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
  Evidence exists that none of the drugs currently available could sustainably lower cumulative diabetes incidence, none has been shown to provide a durable delay in diabetes diagnosis and none has provided a convincing concomitant excess benefit for micro-or macrovascular risk (Diabetes, Obesity and Metabolism)
   
  Predictive models for all-cause and cardiovascular mortality in type 2 diabetic inpatients. A cohort study
  This study provides tools to predict premature mortality in type 2 diabetic inpatients (International Journal of Clinical Practice)
   
  Distinct HbA1c trajectories in a type 2 diabetes cohort
  Four subgroups with distinct HbA1c trajectories were identified. More than 90 % reached and maintained good glycemic control (subgroup one and two). Patients within the two subgroups that showed a more unfavorable course of glycemic control were younger, had higher HbA1c levels and a longer diabetes duration at baseline (Acta Diabetologica)
   
  Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
  This finding suggests that more attention should be given to the management of cardiovascular risk in type 2 diabetic patients with high triglycerides levels (Cardiovascular Diabetology)
   
  Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus
  Results from the first major CV outcome studies in type 2 diabetes, SAVOR-TIMI 53 and EXAMINE, have shown that neither saxagliptin nor alogliptin had increases in major CV events relative to placebo in high-risk patients. Ongoing and future trials will elucidate the CV safety for other DPP-4 inhibitors compared to SUs and the GLP-1 agonists versus placebo (Current Cardiology Reports)
   
  Mental health in adolescents with Type 1 diabetes: results from a large population-based study
  This is one of the first population-based studies to examine mental health of adolescents with Type 1 diabetes. There was no evidence of increased psychopathology across a wide range of mental health measures. These findings contradict previous studies, and suggest that Type 1 diabetes is not associated with an increased risk of psychosocial problems (BMC Endocrine Disorders)
   
  C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register
  Measurement of C-peptide concentration at diagnosis could help identify patients who are at high risk and who presumably would benefit from more intensive treatment (Diabetic Medicine)
   
  Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in people with Type 2 diabetes mellitus, a nationwide longitudinal cohort study
  The results suggest that there is a positive temporal relationship between non-steroidal anti-inflammatory drug use and increased risk of chronic kidney disease in people with Type 2 diabetes. The use of non-steroidal anti-inflammatory drugs should be based on clinical evaluations of benefits and risks, and should be prescribed with caution for people with Type 2 diabetes (Diabetic Medicine)
   
  Generation of Functional Human Pancreatic ß Cells In Vitro
  The cells secrete human insulin into the serum of mice shortly after transplantation in a glucose-regulated manner, and transplantation of these cells ameliorates hyperglycemia in diabetic mice. (Cell)
   
  Initial combination of linagliptin and metformin compared with linagliptin monotherapy in newly diagnosed type 2 diabetes patients with marked hyperglycaemia
  These results support early combination treatment strategies and suggest newly diagnosed, significantly hyperglycaemic individuals may be effectively managed with oral, non-insulin therapy (Diabetes, Obesity and Metabolism)
   
  Empagliflozin (Jardiance®) is accepted for restricted use within NHS Scotland
  Empagliflozin was superior to placebo for glycaemic control in combination with various anti-diabetic medicines (metformin; metformin plus sulphonylurea; thiazolidinedione ± metformin; and insulin) and it was non-inferior to a sulphonylurea in combination with metformin (Scottish Medicines Consortium)
   

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.

Diabetes Weekly News Update - it's FREE!

Subscribe to our free weekly e-mail Please click here if you would like to subscribe to our free weekly e-mail.

Gold Sponsors

Sponsors


Our sponsors have provided unrestricted educational grants for the running of this website. None of these companies have any input to, or editorial control over the content of this website.

Advertisers

The first glucose monitoring device to support insulin therapy management with estimated HbA1c

The first glucose monitoring device to support insulin therapy management with estimated HbA1c.

The Diabetes Times

An online newspaper for the diabetes community.

 

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Book and Product Reviews

Book ReviewsA selection of book and product reviews written by the contributing editors of Glycosmedia.

Read the Reviews >>

FREE Glycosmedia iPhone and iPad App

FREE iPhone AppThe Glycosmedia App for iPhone and iPad is now available to download FREE from the iTunes store via this link.

Recommend Glycosmedia
Recommend Glycosmedia
Sponsorship and Advertising

Why sponsor Glycosmedia? >> click here

If you are interested in sponsorship or advertising opportunities with Glycosmedia then please contact the editor-in-chief Jim Young to discuss the options: jim@glycosmedia.com

 

© Copyright Glycosmedia Partnership
 

Site by Wired up Wales